Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and ...

The Conference on Retroviruses and Opportunistic Infections 2025 (CROI) featured multiple sessions that focused on breaking research and treatments.

A total of 9% of placebo recipients contracted COVID-19 from a household member, compared with 2.9% of ensitrelvir recipients ...

In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from ...

News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...

As scientists gathered at the Conference for Retroviruses and Opportunistic Infections, or CROI, for meetings that run through Wednesday, they face an uncertain future. It was evident in who was ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A 15-year study by Kaiser Permanente Northern California reveals significant gaps in LTBI testing practices, highlighting the need for targeted strategies to prevent active TB cases.

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...

SAN FRANCISCO — During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV survivor, addressed conference attendees and discussed ...